Matthew Jones

Partner, Solicitor

Matthew has extensive experience of acting in large scale UK patent litigation and in multi-jurisdictional patent litigation. Matthew has acted in litigation relating to a wide range of technologies, including electronics, telecommunications, cryptography, optics, mechanical devices, pharmaceuticals and biotechnology.

Before joining EIP, Matthew worked as Senior Counsel for Teva Pharmaceuticals Europe. During his time at Teva, Matthew managed high-profile litigation in the UK, Germany, France and the Netherlands, including Generics [UK] Ltd v Yeda & Teva, which related to the blockbuster drug Copaxone®. Prior to working at Teva, Matthew worked as a solicitor at McDermott Will & Emery and at Taylor Wessing.

Matthew has a degree in Biochemistry from Bristol University and a PhD in Biochemistry (specialising in quantum enzymology) from Leicester University. He has written papers published in peer-reviewed journals and the legal press, and frequently speaks on intellectual property and litigation at business schools, universities and international conferences.


  • RIM -v- Visto.nMatthew was part of the team acting for Visto and working on the UK case involving RIM, which gained notoriety for the legal costs incurred by RIM. (link)
  • GUK (Mylan) -v- Yeda and Teva.nMatthew was the Senior Counsel at Teva with responsibility for this litigation in Europe, which saw success for Teva in multiple jurisdictions including at the UK Court of Appeal. (link)

Education and qualifications

  • 2006 — 2007
    Postgraduate Diploma, University of Bristol
  • 1998 — 2001
    PhD in Biochemistry, University of Leicester
  • 1994 — 1997
    BSc (Hons) in Biochemistry, University of Bristol

Career history

  • 2014 — present
    Partner, EIP
  • 2011 — 2013
    Senior Counsel, Teva Pharmaceutical Industries Ltd
  • 2008 — 2011
    Associate, McDermott Will & Emery
  • 2005 — 2008
    Associate, Taylor Wessing

Additional information

Member of European Patent Lawyers Association (EPLAW)